Insights

    25 November 2026 · 8 min read

    Faster Approvals, Lower Tariffs: Latin America Opens Up for Nordic Medtech

    A bright, modern hospital room with medical equipment in soft daylight

    Nordic medtech has a good name in Latin America. Now the rules are catching up. Brazil and Mexico lean more on trusted foreign regulators, and EU–Mercosur is cutting tariffs on medical devices. Here is what has changed, and how to use it.

    Europe and Brazil on the same list

    On 1 July 2026, the World Health Organization (WHO) published its first list of trusted regulators for medical devices, called WHO Listed Authorities. Twelve regulators are on it. Brazil's ANVISA is one. The European Medical Devices Regulatory Network is another, alongside the US FDA, Health Canada, Australia's TGA, Japan, the UK's MHRA and Swissmedic (ANVISA; RAPS).

    Under this system, other regulators can refer to a listed authority's review results when they approve a device (RAPS). The status is transitional and valid for five years. It does not change any country's rules on its own: each regulator decides how to use the list (ANVISA).

    For Nordic companies, the message is simple: both ends of the corridor are now on the same trusted list.

    Brazil: a faster lane for high-risk devices

    Since June 2024, ANVISA has run a reliance route under Normative Instruction 290/2024. Reliance means a regulator uses another trusted regulator's approval to speed up its own review. The route covers Class III and IV medical devices and in vitro diagnostics (Emergo by UL).

    • Which approvals count: those of the US FDA, Health Canada, Australia's TGA and Japan's health ministry (Emergo by UL; ANVISA). EU CE marking is not on this list today. ANVISA has said it is assessing more authorities (Emergo by UL).
    • How much it is used: by February 2026, ANVISA had received 485 reliance requests and approved 258 (ANVISA, IMDRF Stakeholder Forum, March 2026).
    • What changed in June 2026: when ANVISA needs more information, the company can now answer within 30 days, and ANVISA reassesses within 30 days. Before, the request was rejected and went back into the queue (Emergo by UL).
    • Conditions: the device must be identical to the approved one, with the same intended use. The full Brazilian file is still needed (Emergo by UL).

    In plain terms: if your device already has US, Canadian, Australian or Japanese approval, Brazil now has a shorter road for it.

    Mexico: CE marking can open the door

    Mexico's regulator, COFEPRIS, runs a reliance pathway. It can base its decision on an approval from a trusted foreign authority (Global Regulatory Partners). According to Maven Regulatory Solutions, accepted approvals include CE marking under the EU's Medical Device Regulation, as well as the US FDA and Health Canada.

    • Speed: COFEPRIS must decide within 30 business days on a complete reliance file (Global Regulatory Partners). A standard review takes three to six months (Maven Regulatory Solutions; MedDeviceGuide).
    • Conditions: the product must be the same as the approved one, and the foreign approval must be less than five years old (Global Regulatory Partners).
    • Longer validity: a reform of Mexico's General Health Law, published on 15 January 2026, allows device registrations to be renewed for up to 10 years, up from five (Pure Global).
    The Mexico City skyline along Paseo de la Reforma at sunrise

    Lower tariffs under EU–Mercosur

    The EU–Mercosur interim trade agreement has applied provisionally since 1 May 2026. Mercosur tariffs on medical devices are up to 16% today. They will be phased out, in stages for most devices. The agreement also gives EU medtech the same treatment as local products, and more open public tenders (MedTech Europe).

    Danish, Swedish and Finnish companies benefit directly as EU members. Norwegian companies are covered by the separate Mercosur–EFTA agreement.

    A container port in Brazil at dusk, with cranes and stacked containers

    What Nordic medtech companies should do now

    1. List the approvals you already have. Check which products hold FDA, Health Canada, TGA or Japanese approval for Brazil, and CE marking under the MDR for Mexico.
    2. Align the intended use. Use the same intended use and labels in every market. Differences are a common reason for delays (Emergo by UL).
    3. Choose your local registration holder early. In Brazil, a local company must hold the registration.
    4. Plan the paperwork. Foreign approvals often need an apostille (an official stamp that makes a document valid abroad) and a sworn translation (Emergo by UL).
    5. Check your tariff savings. Ask your customs adviser which devices benefit first, and check the rules of origin.
    6. Look at Brazil and Mexico together. They are Latin America's two largest economies, and both now reward approvals you may already hold.

    “Nordic medtech already has a strong name in Latin America, and now the rules make it easier to prove it. Start with the approvals you already hold, and choose your local partner before you file.”

    Simon Jakobsen — Managing Partner and Co-Founder

    The strategic read

    The road from the Nordics to Latin America is getting shorter. Regulators trust each other more, and tariffs are coming down. Companies that move early, with the right approvals and a local partner, will reach hospitals and patients sooner.

    Use the approvals you already have: Latin America is now set up to reward them.

    This article is general information, not regulatory advice. Please check your own products with a regulatory adviser.

    Sources

    Planning medtech growth in Latin America? We help Nordic healthcare companies choose markets, find local partners and set up registration, from Brazil to Mexico.

    Book a 30-minute introductory call